{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:04:20Z","timestamp":1790805860085,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jbspin.2016.10.004","type":"journal-article","created":{"date-parts":[[2016,12,5]],"date-time":"2016-12-05T14:45:42Z","timestamp":1480949142000},"page":"541-546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Severe gout: Strategies and innovations for effective management"],"prefix":"10.1016","volume":"84","author":[{"given":"Eliseo","family":"Pascual","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janitzia","family":"V\u00e1zquez-Mellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2016.10.004_bib0315","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0320","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0325","first-page":"233","article-title":"Severe tophaceous gout. Characterization of low socioeconomic level patients from M\u00e9xico","volume":"24","author":"V\u00e1zquez-Mellado","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0330","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/annrheumdis-2013-203325","article-title":"Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative","volume":"73","author":"Sivera","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0335","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","author":"Richette","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0340","series-title":"Gout and other crystal arthropathies","first-page":"194","article-title":"Overview of gout therapy strategy and targets, and the management of refractory disease","author":"Liot\u00e9","year":"2012"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0345","first-page":"577","article-title":"Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?","volume":"28","author":"Li-Yu","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0350","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0355","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0360","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2006.060368","article-title":"The time required for disappearance of urate crystals from synovial fluid after successful hypouricemic treatment relates to the duration of gout","volume":"66","author":"Pascual","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0365","doi-asserted-by":"crossref","first-page":"e000075","DOI":"10.1136\/rmdopen-2015-000075","article-title":"Tophus resolution with pegloticase: a prospective dual-energy CT study","volume":"1","author":"Araujo","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0370","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.amjmed.2013.05.009","article-title":"Resolution of massive tophaceous gout with three urate-lowering drugs","volume":"126","author":"Mejia-Chew","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0375","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0380","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0385","first-page":"1650","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0390","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/ard.60.10.981","article-title":"Relation between adverse events associated with allopurinol and renal function in patients with gout","volume":"60","author":"Vazquez-Mellado","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0395","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","article-title":"Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events","volume":"20","author":"Dalbeth","year":"2007","journal-title":"Semin Dial"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0400","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0405","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3899\/jrheum.110092","article-title":"Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions","volume":"38","author":"Chohan","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0410","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3899\/jrheum.111161","article-title":"Febuxostat hypersensitivity","volume":"39","author":"Abeles","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0415","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0420","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10067-006-0528-3","article-title":"Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients","volume":"26","author":"Reinders","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0425","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/annrheumdis-2015-207919","article-title":"Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol","volume":"75","author":"Perez-Ruiz","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0430","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00124743-199904000-00003","article-title":"Treatment of chronic gout in patients with renal function impairment. An open, randomized, actively controlled","volume":"5","author":"Perez-Ruiz","year":"1999","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0435","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0445","first-page":"2093","article-title":"Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study","volume":"34","author":"Richette","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0450","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1136\/annrheumdis-2012-201795","article-title":"Long-term safety of pegloticase in chronic gout refractory to conventional treatment","volume":"72","author":"Becker","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0455","unstructured":"Krystexxa\u00ae Product Label (revised 04\/2012l). Food and Drug Administration. http:\/\/www.fda.gov [accessed 06.02.16]."},{"key":"10.1016\/j.jbspin.2016.10.004_bib0460","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000179595","article-title":"Gouty tophi in the renal medulla in chronic uremia. Study of 17 cases discovered from among 62 autopsies","volume":"4","author":"Verger","year":"1967","journal-title":"Nephron"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0465","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000182373","article-title":"Urate deposits in the renal medulla. Prevalence and associations","volume":"29","author":"Linnane","year":"1981","journal-title":"Nephron"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0470","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5414\/CN108663","article-title":"Revisiting medullary tophi: a link between uric acid and progressive chronic kidney disease?","volume":"85","author":"Ayoub","year":"2016","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0475","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ard.41.1.59","article-title":"Allopurinol treatment and its effect on renal function in gout: a controlled study","volume":"41","author":"Gibson","year":"1982","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0480","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000045783","article-title":"Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts","volume":"86","author":"Perez-Ruiz","year":"2000","journal-title":"Nephron"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0485","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/art.22014","article-title":"Gout and the risk of acute myocardial infarction","volume":"54","author":"Krishnan","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0490","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","article-title":"Independent impact of gout on mortality and risk for coronary heart disease","volume":"116","author":"Choi","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0495","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/art.39581","article-title":"Silent monosodium urate crystals deposits are associated with severe coronary calcification in asymptomatic hyperuricemia: an exploratory study","volume":"68","author":"Andr\u00e9s","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0500","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/art.1780340203","article-title":"Persistence of monosodium urate crystals and low-grade inflammation in synovial fluid of patients with untreated gout","volume":"34","author":"Pascual","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0505","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s10067-006-0292-4","article-title":"Severity of gouty arthritis is associated with Q-wave myocardial infarction: a large-scale, cross-sectional study","volume":"26","author":"Chen","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0510","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2012-202421","article-title":"Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout","volume":"73","author":"Perez-Ruiz","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0515","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/annrheumdis-2012-202594","article-title":"Gout treatment: should we aim for rapid crystal dissolution?","volume":"72","author":"Pascual","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2012.05.025","article-title":"Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial","volume":"125","author":"Taylor","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0525","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3899\/jrheum.140463","article-title":"Treatment target and followup measures for patients with gout: a systematic literature review","volume":"92","author":"Andr\u00e9s","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0530","first-page":"1888","article-title":"Ultrasonographic measurement of tophi as an outcome measure for chronic gout","volume":"34","author":"Perez-Ruiz","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0535","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/rheumatology\/kem246","article-title":"Tophaceous joint disease strongly predicts hand function in patients with gout","volume":"46","author":"Dalbeth","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0540","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000327748","article-title":"The risk of Parkinson disease associated with urate in a community-based cohort of older adults","volume":"36","author":"Jain","year":"2011","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0545","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s00415-009-5170-y","article-title":"Serum uric acid and risk of multiple sclerosis","volume":"256","author":"Massa","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0550","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0555","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1136\/annrheumdis-2015-207984","article-title":"Effects of colchicineon risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims","volume":"75","author":"Solomon","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0560","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","article-title":"Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials","volume":"32","author":"Wortmann","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0565","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1097\/MJT.0b013e31825a364a","article-title":"Colchicine toxicity in end-stage renal disease patients: a case\u2013control study","volume":"21","author":"Solak","year":"2014","journal-title":"Am J Ther"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0570","unstructured":"FDA colchicine data sheet. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022352s017lbl.pdf [accessed 12.09.16]."},{"key":"10.1016\/j.jbspin.2016.10.004_bib0575","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0580","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/BOR.0000000000000031","article-title":"Safety profile of anti-gout agents: an update","volume":"26","author":"Stamp","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0585","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0140-6736(08)60799-0","article-title":"Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial","volume":"371","author":"Janssens","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0590","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1 inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0595","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0600","unstructured":"Ilaris\u00ae Product information. www.ema.euopea.eu [accessed 03.03.16]."},{"key":"10.1016\/j.jbspin.2016.10.004_bib0605","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3899\/jrheum.071229","article-title":"Quality of life and disability in patients with treatment-failure gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0610","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/1471-2474-14-278","article-title":"The effects of commercially available footwear on foot pain and disability in people with gout: a pilot study","volume":"14","author":"Rome","year":"2013","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0615","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3899\/jrheum.140464","article-title":"Interventions for tophi in gout: a Cochrane systematic literature review","volume":"92","author":"Sriranganathan","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.jbspin.2016.10.004_bib0620","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","article-title":"Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study","volume":"72","author":"Rees","year":"2013","journal-title":"Ann Rheum Dis"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X1630197X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X1630197X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T05:57:36Z","timestamp":1536213456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X1630197X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1297319X1630197X"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2016.10.004","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe gout: Strategies and innovations for effective management","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2016.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}